Cargando…

Lym-1 Chimeric Antigen Receptor T Cells Exhibit Potent Anti-Tumor Effects against B-Cell Lymphoma

T cells expressing chimeric antigen receptors (CARs) recognizing CD19 epitopes have produced remarkable anti-tumor effects in patients with B-cell malignancies. However, cancer cells lacking recognized epitopes can emerge, leading to relapse and death. Thus, CAR T cells targeting different epitopes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Long, Hu, Peisheng, Wolfe, Brandon, Gonsalves, Caryn, Ren, Luqing, Khawli, Leslie A., Kaslow, Harvey R., Epstein, Alan L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5751371/ https://www.ncbi.nlm.nih.gov/pubmed/29261129 http://dx.doi.org/10.3390/ijms18122773

Ejemplares similares

Spatio-temporal biodistribution of (89)Zr-oxine labeled huLym-1-A-BB3z-CAR T-cells by PET imaging in a preclinical tumor model
por: Sta Maria, Naomi S., et al.
Publicado: (2021)

Humanized CD30-Targeted Chimeric Antigen Receptor T Cells Exhibit Potent Preclinical Activity Against Hodgkin’s Lymphoma Cells
por: Guo, Jing, et al.
Publicado: (2022)

Autophagy Plays a Critical Role in ChLym-1-Induced Cytotoxicity of Non-Hodgkin’s Lymphoma Cells
por: Fan, Jiajun, et al.
Publicado: (2013)

Antibody targeted CpG for the immunotherapy of solid tumors
por: Epstein, Alan L, et al.
Publicado: (2015)

Principles of N-Linked Glycosylation Variations of IgG-Based Therapeutics: Pharmacokinetic and Functional Considerations
por: Boune, Souad, et al.
Publicado: (2020)

LymPHOS 2.0: an update of a phosphosite database of primary human T cells
por: Nguyen, Tien Dung, et al.
Publicado: (2015)

Prognostic Stratification of Diffuse Large B-cell Lymphoma Using Clinico-genomic Models: Validation and Improvement of the LymForest-25 Model
por: Mosquera Orgueira, Adrián, et al.
Publicado: (2022)

Effects of cobalt-histidine absorbent on aerobic denitrification by Paracoccus versutus LYM
por: Sun, Chaoyue, et al.
Publicado: (2019)

Building Potent Chimeric Antigen Receptor T Cells With CRISPR Genome Editing
por: Liu, Jie, et al.
Publicado: (2019)

Brain Disposition of Antibody-Based Therapeutics: Dogma, Approaches and Perspectives
por: Kouhi, Aida, et al.
Publicado: (2021)

Presence of LYM2 dependent but CERK1 independent disease resistance in Arabidopsis
por: Narusaka, Yoshihiro, et al.
Publicado: (2013)

LymAnalyzer: a tool for comprehensive analysis of next generation sequencing data of T cell receptors and immunoglobulins
por: Yu, Yaxuan, et al.
Publicado: (2016)

Benefits of Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma
por: Zhou, Wenyujing, et al.
Publicado: (2022)

Chimeric antigen receptor (CAR) T-cell treatment for mantle cell lymphoma (MCL)
por: Tbakhi, Bushra, et al.
Publicado: (2022)

A Review of Chimeric Antigen Receptor T-Cell Therapy for Myeloma and Lymphoma
por: Atrash, Shebli, et al.
Publicado: (2021)

Case of Myocarditis After Chimeric Antigen Receptor T Cells With Intracardiac Lymphoma
por: Lee, Dae Hyun, et al.
Publicado: (2022)

Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma
por: Khurana, Arushi, et al.
Publicado: (2022)

Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity
por: Davenport, A. J., et al.
Publicado: (2018)

Access to Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma
por: Snyder, Sophie, et al.
Publicado: (2021)

Additional possibilities of chimeric antigen receptor T-cells in B-cell lymphoma: combination therapy
por: Yang, Yan, et al.
Publicado: (2020)

Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma
por: Yin, Zixun, et al.
Publicado: (2021)

Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas
por: Chu, Fuliang, et al.
Publicado: (2023)

Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study
por: Verhoef, Gregor, et al.
Publicado: (2017)

Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma
por: Zhou, Jin, et al.
Publicado: (2022)

Chimaeric Lym-1 monoclonal antibody-mediated cytolysis by neutrophils from G-CSF-treated patients: stimulation by GM-CSF and role of Fcγ-receptors
por: Ottonello, L, et al.
Publicado: (2001)

Targeting B7-H3 Immune Checkpoint With Chimeric Antigen Receptor-Engineered Natural Killer Cells Exhibits Potent Cytotoxicity Against Non-Small Cell Lung Cancer
por: Yang, Shuo, et al.
Publicado: (2020)

CD8(+) chimeric antigen receptor T cells manufactured in absence of CD4(+) cells exhibit hypofunctional phenotype
por: Lee, Sang Yun, et al.
Publicado: (2023)

Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges
por: Makita, Shinichi, et al.
Publicado: (2019)

Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma
por: Wu, Jiaying, et al.
Publicado: (2022)

FMLP- and TNF-stimulated monoclonal Lym-1 antibody-dependent lysis of B lymphoblastoid tumour targets by neutrophils
por: Ottonello, L, et al.
Publicado: (1999)

Ruxolitinib as Adjunctive Therapy for Hemophagocytic LymPhohistiocytosis after Liver Transplantation: A Case Report and Literature Review
por: He, Kang, et al.
Publicado: (2022)

Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma
por: Strati, Paolo, et al.
Publicado: (2021)

Cardiovascular events in patients treated with chimeric antigen receptor T-cell therapy for aggressive B-cell lymphoma
por: Steiner, Raphael E., et al.
Publicado: (2021)

Outcome Prediction in Patients With Large B-cell Lymphoma Undergoing Chimeric Antigen Receptor T-cell Therapy
por: Voltin, Conrad-Amadeus, et al.
Publicado: (2023)

Chimeric Antigen Receptors for T-Cell Malignancies
por: Scherer, Lauren D., et al.
Publicado: (2019)

Chimeric antigen receptor T-cell therapy
por: Burge, Cale, et al.
Publicado: (2023)

Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma
por: Brammer, Jonathan E, et al.
Publicado: (2021)

Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma
por: Potnis, Kunal C., et al.
Publicado: (2022)

Chimeric antigen receptor‐modified human regulatory T cells that constitutively express IL‐10 maintain their phenotype and are potently suppressive
por: Mohseni, Yasmin R., et al.
Publicado: (2021)

Decitabine enhances cytotoxic effect of T cells with an anti-CD19 chimeric antigen receptor in treatment of lymphoma
por: Li, Sujun, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_9apdqio0l6mqf1fhk269v07v5c